



## B and T Cell-Mediated Immunity 2.0

Guest Editors:

**Dr. Monica A. McArthur**

Center for Vaccine Development,  
University of Maryland School of  
Medicine, Baltimore, MD 21201,  
USA

**Dr. Franklin Toapanta**

Center for Vaccine Development,  
University of Maryland School of  
Medicine, Baltimore, MD 21201,  
USA

Deadline for manuscript  
submissions:

**closed (30 June 2022)**

### Message from the Guest Editors

Dear Colleagues,

Generation of vigorous cell-mediated immune responses is critical to protection against many infectious diseases. T cells and B cells represent separate but interconnected arms of the adaptive immune response. As such, they are critical in providing long-lasting protection, thanks to the induction of immune memory, following vaccination or natural infection. This Special Issue focuses on T and B cell-mediated immunity as they relate to vaccination and protection against infectious diseases. The goal is to enhance our knowledge of the important roles that T and B cells play to provide long-lasting protection. Understanding the contributions of T and B cells, as well as their interactions, following vaccination and/or natural infection could provide critical insights that will help further vaccine development.

Dr. Monica A. McArthur

Dr. Franklin Toapanta

Guest Editors





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)